MAGEC1 as a Candidate Gene for Prostate Cancer
Author Information
Author(s): Henna Mattila, Martin Schindler, Jarkko Isotalo, Tarja Ikonen, Mauno Vihinen, Hannu Oja, Teuvo Tammela, Tiina Wahlfors, Johanna Schleutker
Primary Institution: Institute of Biomedical Technology, University of Tampere
Hypothesis
Can MAGEC1 be identified as a candidate gene for hereditary prostate cancer through microRNA expression profiling?
Conclusion
The study suggests that MAGEC1 may play a role in genetic susceptibility to prostate cancer, particularly in families linked to the HPCX1 locus.
Supporting Evidence
- Seventeen genes were selected for resequencing based on the NMD array, but no truncating mutations were found.
- An association was seen between the MAGEC1 variant and unselected prostate cancer.
- miRNA analysis revealed 29 miRNAs with altered expression between prostate cancer cases and controls.
Takeaway
Researchers looked at genes in families with prostate cancer and found a gene called MAGEC1 that might be important for understanding why some people get this disease.
Methodology
The study used nonsense-mediated mRNA decay (NMD) inhibition and microRNA expression profiling to analyze gene expression and mutations in prostate cancer patients and their healthy brothers.
Potential Biases
The use of healthy brothers as controls may introduce bias due to the late onset of prostate cancer.
Limitations
The study may have missed some mutations due to the complexity of the genomic region and the use of lymphoblastoid cell lines, which may not fully represent prostate tissue.
Participant Demographics
The study involved six prostate cancer patients and their healthy brothers from Finnish families linked to hereditary prostate cancer.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI = 1.10-5.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website